Antibody therapy for rheumatoid arthritis.
High-quality monoclonal antibodies (mAbs) with specificity for relevant disease molecules can now be produced in abundance. Anti-tumour necrosis factor-alpha therapies have set a new standard for symptom control in rheumatoid arthritis, and blockade of tumour necrosis factor has the potential to pro...
第一著者: | Taylor, P |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2003
|
類似資料
-
Humanised monoclonal antibody therapy for rheumatoid arthritis.
著者:: Isaacs, J, 等
出版事項: (1992) -
HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS
著者:: Isaacs, J, 等
出版事項: (1992) -
Anti-cytokine therapy for rheumatoid arthritis.
著者:: Maini, R, 等
出版事項: (2000) -
Anti-TNFalpha therapy for rheumatoid arthritis: an update.
著者:: Taylor, P
出版事項: (2003) -
Antikeratin antibodies in rheumatoid arthritis
著者:: J Zabek
出版事項: (2003-02-01)